ArriVent BioPharma, Inc. (NasdaqGM: AVBP)
Health Care · Biotechnology · US
$16.73
-40.82% today · -20.0% 1Y
ArriVent BioPharma, Inc. (NasdaqGM: AVBP) operates in the Biotechnology industry within the Health Care sector. The company is valued at $824.92M and employs 77 people.
Over the last twelve months the share price has lost 20.0%, trading between 11.36 and 35.83.
Tweenvest scores ArriVent BioPharma, Inc. across four factors: quality 38/100, value 36/100. Its strongest factor is quality.
AVBP price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $824.92M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -3.70
- Dividend yield
- —
- Beta (5Y)
- 1.35
- 52-week high
- $35.83
- 52-week low
- $11.36
- Avg volume (3M)
- —
- Shares outstanding
- 49.31M
- Employees
- 77
- Next earnings
- —
About ArriVent BioPharma, Inc.
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
- ISIN
- US04272N1028
- Founded
- 2021
- Listed since
- Jan 26, 2024
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Sana Biotechnology, Inc.NasdaqGS: SANA | $835.22M | $2.79 | 0.00% |
| Arbutus Biopharma CorporationNasdaqGS: ABUS | $834.92M | $4.22 | +0.96% |
| Oxford Biomedica plcLSE: OXB | $834.48M | £5.21 | -4.23% |
| CARsgen Therapeutics Holdings LimitedSEHK: 2171 | $833.26M | HK$11.63 | -6.59% |
| Ardelyx, Inc.NasdaqGM: ARDX | $817.34M | $3.28 | +0.31% |
| Geron CorporationNasdaqGS: GERN | $787.03M | $1.23 | +0.41% |
| Immix Biopharma, Inc.NasdaqCM: IMMX | $784.26M | $9.46 | -2.27% |
| Achieve Life Sciences, Inc.NasdaqCM: ACHV | $762.51M | $7.41 | +2.35% |
Figures last refreshed Oct 11, 2026.